[Association between the expression of IGF1R and estrogen receptor and efficacy of neoadjuvant chemotherapy in beast cancer patients].

Abstract

OBJECTIVE:

To detect the expression of IGF1R and estrogen receptor, and to explore the relationship between their expression and the pathological complete response (pCR) rate of neoadjuvant chemotherapy (docetaxel plus epirubicin) in breast cancer patients.

METHODS:

We selected 139 women with breast cancer who underwent neoadjuvant chemotherapy (docetaxel plus epirubicin), and detected the expression of IGF1R and estrogen receptor in the samples taken before chemotherapy by Immunohistochemistry. The association between their expression and pCR rate of neoadjuvant chemotherapy was analyzed.

RESULTS:

Among the 139 cases, IGF1R was highly expressed in 45.3% (63/139) cases, and ER was positively expressed in 62.6% (87/139) cases. IGF1R was highly expressed in 54.0% (47/87) of the ER+ cases, significantly higher than that of ER- cases (30.8%, P<0.01). The overall pCR rate of all the 139 patients who received docetaxel plus epirubicin as neoadjuvant chemotherapy was 10.1% (14/139). The pCR rate was 19.2% (10/52) of the ER- patients and 4.6% (4/87) of the ER+ patients (P<0.05). The pCR rate was 10.5% (8/76) in the patients with low IGF1R expression and 9.5% (6/63) in the patients with high IGF1R expression (P>0.05). The patients with negative expression of ER and high expression of IGF1R showed the highest pCR rate (31.2%, P<0.01).

CONCLUSIONS:

Breast cancer patients with negative expression of ER and high expression of IGF1R are more sensitive to neoadjuvant chemotherapy of docetaxel plus epirubicin, and their pCR rate is significantly higher than that of other patients.

• Authors: Lei Liu, Xiru Li, Jin Zhang
• Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] (Zhonghua Zhong Liu Za Zhi) Vol. 37 Issue 11 Pg. 833-6 (Nov 2015) ISSN: 0253-3766 [Print] China
• PMID: 26887513 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• IGF1R protein, human
• Receptors, Estrogen
• Receptors, Somatomedin
• Taxoids
• Docetaxel
• Epirubicin
• Receptor, IGF Type 1

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Tumor
• Breast Neoplasms (drug therapy, metabolism)
• Docetaxel
• Epirubicin (administration & dosage)
• Female
• Humans
• Immunohistochemistry
• Neoadjuvant Therapy
• Receptor, IGF Type 1
• Receptors, Estrogen (metabolism)
• Receptors, Somatomedin (metabolism)
• Taxoids (administration & dosage)